Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Binimetinib + Encorafenib in Non-V600 BRAF Mutant Cancers
NCT03843775Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Feb 2019
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of binimetinib, encorafenib in advanced malignant solid tumor, sponsored by Memorial Sloan Kettering Cancer Center. Started Feb 2019; status: completed.
02
Drugs
binimetinibencorafenib
03
Conditions
advanced malignant solid tumor
Beyond the preview
Go deeper on NCT03843775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03843775.